cassava7
Senior Member (Voting Rights)
The summary of the IOM report reads (p. 10, bolding mine):
Do we know if any of the US advocacy organizations -- Solve ME, the US ME/CFS Clinicians Coalition, perhaps OMF -- has approached the NAM in this regard, or if the NAM itself has expressed its intention to update the report?
@Medfeb
ETA: Ellen Wright Clayton, who chaired the IOM committee for the ME/CFS report, remains an elected member of the NAM.
It is encouraging to note that progress already is being made in understanding the etiology, natural history, pathophysiology, and effective treatment of ME/CFS using a variety of physiological and molecular methods. Several large cohort studies are now under way. The committee expects that this research will lead to findings that can be used to further refine the diagnosis of this disorder and the elaboration of clinically pertinent sub-types. As a result, the committee calls for a reevaluation of the evidence in no more than 5 years using the methods recommended in the IOM report Clinical Practice Guidelines We Can Trust (IOM, 2011).
Although it can be said that the committee's expectations have not been met, the delay of 5 years has already passed (the report having been published in 2015).
Do we know if any of the US advocacy organizations -- Solve ME, the US ME/CFS Clinicians Coalition, perhaps OMF -- has approached the NAM in this regard, or if the NAM itself has expressed its intention to update the report?
@Medfeb
ETA: Ellen Wright Clayton, who chaired the IOM committee for the ME/CFS report, remains an elected member of the NAM.
Last edited: